The Leukemia & Lymphoma Society Partnering Day
The Leukemia & Lymphoma Society’s (LLS) Therapy Acceleration Program (TAP) is actively seeking to build business alliances with companies that have oncology, inflammation, anti-infective and cancer supportive care or similar assets with the potential to change the standard of care for blood cancer patients.
With an annual alliance budget of $20M, The Leukemia & Lymphoma Society’s (LLS) Therapy Acceleration Program (TAP) past investments range from $150K to $12.5M in a form of milestone payments.
Ideal applicants will have therapeutics or diagnostics that target novel mechanisms of action and can provide the scientific rationale for pursuing the blood cancer space, well-designed clinical regulatory strategy and future plan. Additionally, the companies most likely to be chosen for meetings will be in late-preclinical (the last of IND enabling studies), or in clinical development.
The Leukemia & Lymphoma Society recognizes that many companies pursuing solid tumor indications have assets that may be of value in the blood cancer space, but for financial or strategic reasons are not exploring blood cancer indications. These companies and assets are of interest to LLS as the role for LLS is to broaden the opportunities for drug development for blood cancers.
LLS cost shares with companies along an agreed upon timeline, with milestones and deliverables, tranches its funding accordingly, and negotiates a fair return on its investment should the asset be successfully developed for patients.
TAP is more likely to fund projects that will potentially net key results that will enable a company to partner or raise additional funding to complete the testing, registration and marketing of new therapies or diagnostics for a blood cancer indication.
LLS brings significant expertise from its team of former biotech and pharma drug development professionals and its patient services department to assist with information about trials and accrual of patients. The LLS has been chosen as a partner of choice by more than 20 alliance partners that have participated in TAP since 2007.
In order to be selected, companies will need to demonstrate:
- the therapeutic potential of its drug candidate;
- the capabilities of its management and scientific staff;
- its financial strength;
- its freedom to operate, including intellectual property protection;
- well-designed regulatory and commercialization strategies.
Chief Mission Officer
Keting Chu, MD & PhD
VP, Research Therapy Acceleration Program
VP, Research Business Development
|What:||The Leukemia & Lymphoma Society Partnering Day|
|When:||Thursday, February 7, 2013
8:30AM – 10:00AM
Plenary Breakfast: Corporate Overview
10:00AM – 6:00PM
One-on-One Partnering Meetings
249 E Grand Avenue
South San Francisco, CA 94080
View Map and driving directions
|Parking:||Free Parking Available|
|Register for General Plenary Apply for One-on-One Meeting|
|Plenary Breakfast: Corporate Overview is free to attend. Advanced registration is required due to space limitations.Application is required for one-on-one meetings. Only companies reviewed and approved will be scheduled for a one-on-one partnering meeting. Application review is on a rolling basis, so we suggest applying early due to a limited number of available appointments.|
|Attire:||Business attire suggested|